Galectin Therapeutics Reports 2023 Financial Results and Pro

29.03.2024 - NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended ...

Related Keywords

, Richard Uihlein , Chris Calabrese , Jack Callicutt , Khurram Jamil , Kevin Gardner , Benjamins Carson , Pol Boudes , Company Annual Report On Form , Belapectin Program , Drug Administration , Company Contact , Exchange Commission , Galectin Therapeutics Inc , Chief Medical Officer , Fast Track Designation , Data Safety , Monitoring Board , Liver Meeting , American Association , Liver Diseases , Annual Report , Fast Track , Private Securities Litigation Reform Act , Chief Financial , Relations Contacts , Galectin Therapeutics , Galectin Therapeutic , Consolidated Statements , Galectin Therapeutics Chart , Alectin Therapeutics Kurs , Alectin Therapeutics Aktie ,